Youcare Pharmaceutical (SH:688658) Hua Yuan Zheng Quan·2025-06-29 23:30Investment Rating - Investment rating: Positive (maintained) [4] Core Viewpoints - The domestic siRNA therapy is accelerating, with a focus on YK Pharmaceuticals. siRNA (Small interfering RNA) shows significant potential in treating cardiovascular, metabolic, and cancer diseases due to its high specificity, short development time, and long-lasting efficacy [3][10][15] - The report emphasizes the importance of innovative drugs as a main theme for the year, while also highlighting opportunities in overseas markets and aging-related consumption [20][37] Summary by Sections Domestic siRNA Therapy - The report highlights the rapid rise of siRNA therapies in China, with 7 siRNA drugs approved globally, including Novartis' Leqvio (Inclisiran), which is projected to achieve sales of $754 million in 2024 [11][12] - Domestic companies are actively engaging in significant business development (BD) transactions in the siRNA field, with notable deals such as the $4.165 billion agreement between Boao Pharmaceutical and Novartis [15][19] - YK Pharmaceuticals is particularly noted for its comprehensive nucleic acid technology platform and ongoing clinical trials for its siRNA candidates targeting high cholesterol and hypertension [15][20] Industry Performance - From June 23 to June 27, the pharmaceutical index rose by 1.60%, with a total of 416 stocks increasing in value, while 71 stocks declined [5][20] - Key performers included innovative drug companies such as Shenzhou Cell and Haobio, while stocks like YK Pharmaceuticals experienced declines [5][21][22] Investment Recommendations - The report suggests focusing on innovative drugs and medical devices, particularly those with strong business development catalysts in the second half of the year [4][37] - Specific companies recommended for investment include Heng Rui Pharmaceutical, Keren Pharmaceutical, and Xinda Biopharmaceutical [4][42]